Key facts
- It has raised $4.5M; the latest was Early Stage VC ($4.5M) in May 2025.
- Notable investors include 3LB Seed Capital, Claris Ventures, Exor.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Lever Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Lever Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lever Bio
Operator of a biotechnology company designed to develop next-generation immuno-oncology therapies. The company's technology leverages metabolic and immune system reprogramming to overcome resistance to existing cancer treatments by enhancing the recruitment, activation, and sustained function of cytotoxic T lymphocytes against solid tumors, enabling healthcare professionals to improve patient outcomes.
- Sector
- Healthcare
- HQ
- Turin, Italy
- Founded
- 2024
- Employees
- 1
- Website
- leverbio.com/
- Ownership
- Privately Held (backing)
Lever Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lever Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lever Bio in its N-PORT filings yet. We sweep new filings monthly.